EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Development of Selective Antitumor Inhibitors That Target PARP-1

Fang Liu, Jiashu Chen, Xiangqian Li, Ruihua Liu, Yiting Zhang, Chenxia Gao, Dayong Shi iD

Journal of Medicinal Chemistry · 28.12.2023 · 66 (24) · 16464-16483

DOI: 10.1021/acs.jmedchem.3c00865 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.12.2023. Verfasst von Fang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237 Shandong P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Shandong Province, Key Technology Research and Development Program of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a major threat to the lives and health of people around the world, and the development of effective antitumor drugs that exhibit fewer toxic effects is an important aspect of cancer treatment. PARP inhibitors are antitumor drugs that target pathways involved in DNA-damage repair. The currently approved PARP inhibitors include olaparib, niraparib, rucaparib, talazoparib, fuzuloparib, and pamiparib. Hematological toxicities associated with the simultaneous inhibition of PARP-1 and PARP-2 have limited the clinical applications of these drugs. The present review introduces the necessity for research on the development of selective PARP-1 inhibitors from the perspective of structural and functional mechanisms of PARP-1 inhibition. A review of recently reported selective PARP-1 inhibitors provides the foundation for exploring novel strategies for designing selective PARP-1 inhibitors from the perspective of structure-activity relationships combined with computer simulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansPoly(ADP-ribose) Polymerase InhibitorsDNA Repair

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237 Shandong P. R. China.

ORCID-Profile: Dayong Shi

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Shandong Province
  • Key Technology Research and Development Program of Shandong Province
  • Qingdao Science and Technology Benefit People Demonstration Guide Special Project
  • Qingdao Emerging Industry Cultivation Project

Zitieren

APA

Liu, F., Chen, J., Li, X., Liu, R., Zhang, Y., Gao, C., & Shi, D. (2023). Advances in Development of Selective Antitumor Inhibitors That Target PARP-1. Journal of Medicinal Chemistry, 66(24), 16464-16483. https://doi.org/10.1021/acs.jmedchem.3c00865

Vancouver

Liu F, Chen J, Li X, Liu R, Zhang Y, Gao C, et al. Advances in Development of Selective Antitumor Inhibitors That Target PARP-1. Journal of Medicinal Chemistry. 2023;66(24):16464-16483. doi:10.1021/acs.jmedchem.3c00865

BibTeX
@article{Liu2023,
  author = {Liu, Fang and Chen, Jiashu and Li, Xiangqian and Liu, Ruihua and Zhang, Yiting and Gao, Chenxia and Shi, Dayong},
  title = {Advances in Development of Selective Antitumor Inhibitors That Target PARP-1},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {24},
  pages = {16464--16483},
  doi = {10.1021/acs.jmedchem.3c00865}
}
Kostenlos starten →